Peptides or small molecules? Different approaches to develop more effective CDK inhibitors
D Cirillo1, F Pentimalli, A Giordano
1INT-CROM, Pascale Foundation, National Cancer Institute - Cancer Research Center, Mercogliano, Italy, 83013, Mercogliano Avellino, Italy. Donatella.cirillo@cro-m.eu
Current Medicinal Chemistry
|June 10, 2011
Summary
This review explores cyclin-dependent kinase (CDK) inhibitors for cancer therapy, detailing structure-activity relationships (SAR) of peptides versus small molecules to guide future drug development.
Area of Science:
- Molecular Biology
- Biochemistry
- Pharmacology
Background:
- Cell cycle regulation is vital for cellular survival, preventing uncontrolled division and repairing genetic damage.
- Cyclins and cyclin-dependent kinases (CDKs) orchestrate cell cycle progression; their dysregulation is a hallmark of cancer.
- Developing CDK inhibitors is a key strategy to combat cancer by modulating cell cycle control.
Purpose of the Study:
- To review major classes of CDK inhibitors.
- To focus on structure-activity relationship (SAR) studies of these inhibitors.
- To discuss the pharmacological and therapeutic implications of CDK inhibition.
Main Methods:
- Literature review of existing CDK inhibitors.
- Analysis of structure-activity relationships (SAR) for peptide and small molecule inhibitors.
- Discussion of pharmacokinetic properties and specificity.
Main Results:
- Peptide inhibitors offer high selectivity but poor pharmacokinetics.
- Small molecule inhibitors have better pharmacokinetic profiles but lower specificity.
- Ongoing research focuses on optimizing inhibitor design for therapeutic efficacy.
Conclusions:
- CDK inhibitors represent a promising therapeutic avenue for cancer treatment.
- Balancing selectivity and pharmacokinetic properties is crucial for effective drug design.
- Further SAR studies are essential for developing potent and safe CDK-targeted therapies.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...